| Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors (NCT02636036) | Akamis Bio | 2016-01-25 |
| Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck (NCT01998542) | Mirror Biologics, Inc. | 2016-01-01 |
| Comparison of Two Concomitant Administration of RT With Cisplatin in Standard Infusion or Fractional Infusion (NCT03330249) | Groupe Oncologie Radiotherapie Tete et Cou | 2015-12-03 |
| Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer (NCT02551159) | AstraZeneca | 2015-10-15 |
| A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients (NCT02473731) | Celldex Therapeutics | 2015-10-01 |
| ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors (NCT02565758) | AbbVie | 2015-09-18 |
| SUPREME-HN A Retrospective Cohort Study of PD-L1 in Recurrent and Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) (NCT02543476) | AstraZeneca | 2015-09-16 |
| Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer (NCT02572778) | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 2015-09-01 |
| Safety Study of MGD009 in B7-H3-expressing Tumors (NCT02628535) | MacroGenics | 2015-09-01 |
| Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib (NCT02538627) | Merrimack Pharmaceuticals | 2015-08-01 |
| Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (NCT02277197) | James J Lee | 2015-08-01 |
| A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors (NCT02452424) | Daiichi Sankyo | 2015-07-02 |
| Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma (NCT02454179) | Acerta Pharma BV | 2015-05-01 |
| Safety Study of AMG 228 to Treat Solid Tumors (NCT02437916) | Amgen | 2015-04-21 |
| Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies (NCT02369458) | Washington University School of Medicine | 2015-04-14 |
| Study of LEE011plus Cetuximab in Patients With a Cancer of the Head and Neck (NCT02429089) | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 2015-04-01 |
| Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma (NCT02296684) | Washington University School of Medicine | 2015-03-25 |
| Safety Study of SEA-CD40 in Cancer Patients (NCT02376699) | Seagen Inc. | 2015-02-28 |
| Valproic Acid Plus Cisplatin and Cetuximab in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck (NCT02624128) | National Cancer Institute, Naples | 2015-02-23 |
| Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer (NCT02350712) | Daiichi Sankyo | 2014-12-01 |
| Post-marketing Surveillance Study of Docetaxel-Based Chemotherapy (NCT02972216) | Yung Shin Pharm. Ind. Co., Ltd. | 2014-11-01 |
| A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab (NCT02124850) | Celgene | 2014-10-28 |
| A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer (NCT02262741) | MedImmune LLC | 2014-10-15 |
| Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck (NCT02158234) | H. Lee Moffitt Cancer Center and Research Institute | 2014-07-16 |
| Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN (NCT02124707) | UNC Lineberger Comprehensive Cancer Center | 2014-06-16 |
| Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) (NCT02105636) | Bristol-Myers Squibb | 2014-05-29 |
| Resource Sparing Curative Radiotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck: The HYPNO Trial (NCT02765503) | International Atomic Energy Agency | 2014-03-01 |
| Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer (NCT02031250) | University of Michigan Rogel Cancer Center | 2014-02-01 |
| The Role of Chromoendoscopy in the Early Detection of Esophageal Cancer in Patients With Prior Head and Neck Cancers (NCT02435602) | Maria Sklodowska-Curie National Research Institute of Oncology | 2013-12-01 |
| Understanding GRID Radiation Therapy Effects on Human Tumor Oxygenation and Interstitial Pressure to Increase Translation of Solid Tumor Therapy (NCT01967927) | University of Arkansas | 2013-12-01 |
| ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer (NCT02002182) | Andrew Sikora | 2013-12-01 |
| Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC) (NCT01984892) | Nina Bhardwaj | 2013-11-01 |
| Debio 1143-201 Dose-finding and Efficacy Phase I/II Trial (NCT02022098) | Debiopharm International SA | 2013-10-01 |
| Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC) (NCT01716416) | Washington University School of Medicine | 2013-05-31 |
| Reproducibility of Intratumor Distribution of 18F-EF5 in Head and Neck Cancer (NCT01774760) | Turku University Hospital | 2013-03-01 |
| Collection of Plasma Samples for Squamous Cell Carcinoma of the Head and Neck Patients (NCT02139020) | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 2013-02-01 |
| Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer (NCT01783587) | Dana-Farber Cancer Institute | 2013-02-01 |
| A Phase II Study to Evaluate Low-Dose Fractionated Radiotherapy (LDFRT) (NCT01820312) | University of Arkansas | 2013-01-01 |
| Dacomitinib Plus Radiotherapy, With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck (NCT01737008) | University Health Network, Toronto | 2013-01-01 |
| A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC. (NCT01732640) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2012-12-01 |
| Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History (NCT01758731) | University of Colorado, Denver | 2012-10-22 |
| Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery (NCT01612351) | UNC Lineberger Comprehensive Cancer Center | 2012-06-01 |
| Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma (NCT00903461) | University of Pittsburgh | 2012-04-01 |
| Study Comparing Two Treatments in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (NCT01528163) | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 2012-02-01 |
| Performance of PET 18 F-FDG Coupled to CT With Contrast Injection Iodized in the Diagnosis of Early Recurrences of Head and Neck Carcinoma Treated With Concurrent Chemoradiation. Comparison With 18F-FDG PET Coupled With CT Not Injected With Filling CT Standard Injection (NCT02510872) | University Hospital, Caen | 2011-12-01 |
| Randomised Phase II, Cetuximab in Combination With 5FU and Cisplatin or Carboplatin Versus Cetuximab in Combination With Paclitaxel and Carboplatin for Treatment of Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck (NCT01830556) | Karolinska University Hospital | 2011-11-01 |
| Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck (NCT01458392) | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | 2011-10-01 |
| Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma (NCT01488318) | Julie E. Bauman, MD, MPH | 2011-09-01 |
| Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study (NCT01221753) | Dana-Farber Cancer Institute | 2011-07-01 |
| Study of DCA (Dichloroacetate) in Combination With Cisplatin and Definitive Radiation in Head and Neck Carcinoma (NCT01386632) | Sanford Health | 2011-05-01 |
| Cabazitaxel - PF Induction Chemotherapy (NCT01379339) | Krzysztof Misiukiewicz | 2011-04-01 |
| ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma (NCT01218048) | Robert Ferris | 2011-02-01 |
| Identification of Gene Expression Signature for Panitumumab Sensitivity in Untreated Locally Advanced SCCHN (NCT01305772) | Neal Ready | 2011-01-01 |
| Nutrition and Life QUality Patients With Head and Neck Cancers (NCT02510859) | University Hospital, Caen | 2010-12-01 |
| Interstitial Photodynamic Therapy (PDT) With Temoporfin for Advanced Head and Neck Cancers (NCT01415986) | University of Arkansas | 2010-11-01 |
| EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck (NCT01360827) | Merck KGaA, Darmstadt, Germany | 2010-08-01 |
| Effectiveness in Head and Neck Cancer Detection Using Positron Emission Tomography (PET) Insert Device (NCT01133262) | Washington University School of Medicine | 2010-06-01 |
| Combination of Cisplatin, Cetuximab and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (NCT01015664) | University of Tennessee Cancer Institute | 2010-02-01 |
| Phase II Study of RAD001 Head and Neck Cancer (NCT01051791) | Julie E. Bauman, MD, MPH | 2010-01-01 |
| A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck (NCT01177956) | Merck KGaA, Darmstadt, Germany | 2009-12-01 |
| Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin (NCT00999700) | Gruppo Oncologico del Nord-Ovest | 2009-09-01 |
| Study of Cetuximab in Combination With Chemotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) (NCT00971932) | Merck KGaA, Darmstadt, Germany | 2009-07-01 |
| Active Immunization of Patients With Carcinoma of Oral Cavity or Oropharynx With Autologous Dendritic Cells Transfected With DNA From Autologous Tumor (NCT00377247) | University of Pittsburgh | 2009-04-01 |
| Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects (NCT01012258) | Merck KGaA, Darmstadt, Germany | 2009-02-01 |
| Azacitidine and Cisplatin in Patients With Advanced Lung or Head and Neck Cancer (NCT00901537) | Loma Linda University | 2009-02-01 |
| Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck Cancer (NCT00736944) | Washington University School of Medicine | 2008-12-19 |
| Hypoxia-based Dose Escalation With Radiochemotherapy in Head and Neck Cancer (NCT02352792) | University Hospital Tuebingen | 2008-12-01 |
| Stereotactic Body Radiotherapy for Head and Neck Tumors (NCT01344356) | Mercy Research | 2008-07-01 |
| Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors (NCT00625456) | Jennerex Biotherapeutics | 2008-06-01 |
| Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (NCT01104922) | David A. Clump, MD, PhD | 2007-12-26 |
| Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck (NCT00570674) | Dana-Farber Cancer Institute | 2007-11-01 |
| Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck (NCT00513383) | Massachusetts General Hospital | 2006-04-01 |
| Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer (NCT00272181) | Sesen Bio, Inc. | 2006-01-01 |
| Erlotinib,Radiation and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck (NCT00442455) | Grupo de Investigación Clínica en Oncología Radioterapia | 2006-01-01 |
| 0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck (NCT00257738) | University of Maryland, Baltimore | 2005-11-01 |
| Study of 3-Dimensional Conformal Radiotherapy (3D-CRT) Versus Intensity Modulated Radiotherapy (IMRT) for Head and Neck Squamous Cell Carcinoma (HNSCC) (NCT00652613) | Tata Memorial Hospital | 2005-08-01 |
| A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer (NCT00210470) | Brooklyn ImmunoTherapeutics, LLC | 2005-07-01 |
| Study of Unilateral Neck Irradiation in Patients With SCC of the Head and Neck (NCT00206752) | Beth Israel Medical Center | 2004-08-01 |
| Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX) (NCT00206219) | AstraZeneca | 2003-11-01 |